KPV is a tiny peptide made of just three amino acids: lysine, proline and valine (Lys-Pro-Val). It is the tail end of alpha-MSH, a natural hormone, and scientists study it because it appears to calm inflammation in cell and animal experiments without the skin-darkening effect of its parent hormone. This plain-English guide explains what KPV peptide is, where it comes from, how researchers think it works, what the studies have actually found and where the evidence stops.
What is KPV peptide?
KPV is a tripeptide, which simply means a chain of three amino acids joined by peptide bonds. The name comes from the one-letter codes for those amino acids: K for lysine, P for proline and V for valine. If you want a refresher on how peptides are named by length, our guide to the different types of peptides explains terms like dipeptide, tripeptide and polypeptide.
Because it is so short, KPV is a very small molecule. Its formula is C16H30N4O4 and its molecular weight is roughly 342 g/mol, which is tiny next to most research peptides. For comparison, BPC-157 has 15 amino acids and growth hormone has 191.
KPV is not a newly invented compound. It occurs naturally as part of a larger hormone, and that is where the story starts.
Where KPV comes from: alpha-MSH
Alpha-melanocyte-stimulating hormone (alpha-MSH) is a peptide hormone with 13 amino acids. The body cuts it from a large precursor protein called proopiomelanocortin, or POMC. Alpha-MSH is best known for its role in skin pigmentation, but it also acts on immune cells and the brain. You can read more about how hormones like this are made in our explainer on peptide hormones.
KPV is positions 11 to 13 of alpha-MSH, the very last three amino acids of the chain. Researchers found that this short end piece held on to a surprising amount of the hormone’s anti-inflammatory activity in lab tests. A detailed review from the University of Münster sums up the work on alpha-MSH and its related tripeptides, and notes that KPV keeps the anti-inflammatory effect while lacking the pigment-related action of the full hormone (Brzoska and colleagues, Endocrine Reviews, 2008).
How KPV is thought to work
The honest answer is that the mechanism is still being worked out. Researchers have proposed a few overlapping ideas.
- Calming inflammatory signals inside cells. In cell experiments, KPV reduced the activity of NF-κB and MAP kinase pathways. These are switches that turn on inflammatory messengers called cytokines.
- Getting into cells through a peptide transporter. Gut lining cells carry a transporter called PepT1, which moves small di- and tripeptides into cells. Researchers found that KPV is carried in by PepT1, and PepT1 levels rise in the inflamed colon.
- Melanocortin receptors, possibly. Alpha-MSH works through melanocortin receptors such as MC1R. Whether KPV relies on these receptors is debated. Some studies suggest its effects are at least partly independent of MC1R.
A study at the University of Sheffield looked at how alpha-MSH and KPV signal in human skin cells (keratinocytes). It found that both peptides triggered calcium signals rather than raising cyclic AMP, the messenger usually linked to MC1R (Elliott and colleagues, Journal of Investigative Dermatology, 2004). It is a good example of how a three-amino-acid peptide can still have complicated biology.
What does the research on KPV show?
Most published KPV research falls into two areas: gut inflammation models and skin cell studies. Almost all of it is preclinical, meaning it was done in cells or animals.
KPV in gut inflammation models
The best-known KPV paper comes from Emory University. The team showed that tiny (nanomolar) amounts of KPV reduced inflammatory signalling and cytokine release in human gut and immune cell lines. They also showed that KPV enters these cells through PepT1. In two mouse models of chemically induced colitis, KPV lowered markers of inflammation (Dalmasso and colleagues, Gastroenterology, 2008).
A separate group at the University of Münster tested KPV in two mouse colitis models and reported fewer inflammatory cells in the colon tissue. Interestingly, KPV still had an effect in mice with a non-working MC1R receptor, which is why researchers think it does not depend only on that receptor (Kannengiesser and colleagues, Inflammatory Bowel Diseases, 2008).
Later work has focused on delivery, for example packaging KPV into nanoparticles designed to release it in the colon of mice. That research is about how to get the peptide to the right place, which is a common challenge with peptides.
KPV in skin cell research
Because alpha-MSH is so closely linked to skin, many KPV studies use skin cells. Alongside the Sheffield signalling work, the Münster review describes animal models of skin inflammation, such as irritant and allergic contact dermatitis, where alpha-MSH and its tripeptides were studied.
KPV vs alpha-MSH: key differences
| KPV | Alpha-MSH | |
|---|---|---|
| Length | 3 amino acids | 13 amino acids |
| Sequence | Lys-Pro-Val | Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val |
| Origin | C-terminal fragment of alpha-MSH | Cut from the precursor POMC |
| Pigment-related activity | Described as lacking it | Yes, via MC1R |
| Main receptor route | Debated; PepT1 transport shown in gut cells | Melanocortin receptors (MC1R, MC3R, MC4R, MC5R) |
What the KPV evidence does not show
It is easy to read headlines about “anti-inflammatory peptides” and assume far more than the studies support. Keep these limits in mind:
- The evidence is mainly preclinical. Cell and mouse findings often do not carry over to people, and KPV has not been established in clinical trials.
- Models are not real-world conditions. Chemically induced colitis in mice is a useful lab tool, but it is a simplified version of a complex process.
- A study is not proof about a product. A paper about KPV does not show that any particular vial has the same effect. That depends on identity and purity, which is why testing matters.
KPV for laboratory research: quality and handling
If you are planning KPV experiments, the basics are the same as for any research peptide. Check identity and purity first. Each batch should come with a certificate of analysis showing HPLC purity and mass spectrometry identity, and our guide on how to read a peptide certificate of analysis walks through what each section means.
KPV is supplied as a freeze-dried powder. Like other lyophilised peptides it is best kept cold, dry and protected from light, with extra care once it is in solution. Our guide to storing research peptides and their shelf life covers temperatures, moisture and freeze-thaw cycles.
At Peptides UK, our KPV research peptide is HPLC & COA Verified, and every batch is Third-Party HPLC Verified. Like all of our products, it is for laboratory research use only and is not intended for human or veterinary use.
KPV peptide: frequently asked questions
What does KPV stand for?
KPV is the one-letter code for its three amino acids: lysine (K), proline (P) and valine (V). Written in three-letter code it is Lys-Pro-Val.
Is KPV the same as alpha-MSH?
No. KPV is only the last three amino acids of alpha-MSH, which is 13 amino acids long. It keeps much of the anti-inflammatory activity seen in lab studies of alpha-MSH, but it is a different, much smaller molecule.
Does KPV affect pigmentation like melanotan?
Reviews of the alpha-MSH literature describe KPV as lacking the pigment-related activity of full-length alpha-MSH. That is one of the main reasons researchers became interested in it as a separate tool compound.
Is KPV an approved medicine?
No. KPV has not been through the clinical trials needed to become a licensed medicine. Most of what is known comes from cell and animal studies, and KPV supplied by Peptides UK is for laboratory research use only.
How is KPV usually stored in the lab?
Like most research peptides, KPV is supplied as a freeze-dried (lyophilised) powder. It is usually kept cold, dry and away from light, and once in solution it is generally kept refrigerated and used within a set period. Our storage guide covers the details.
